There are 41 papers on critical limb ischemia in aging research: 1 trial and 28 observational studies in people, 4 in animals, 8 reviews.
41 papers study it23 more mention it6 findings
See all 64 papers on critical limb ischemia
“Individual endpoints including CLI (RR: 0.50, 95% CI: 0.39-0.63, P <0.001)”
- Human trial1
- Humans28
- Animals4
Effects
1Lifespan
downin humans1
1 study
Lifespan
downin humans1
Critical limb ischemia is linked with lower lifespan in humans (chronic critical limb ischemia) (decreased by 9 years).
Humanschronic critical limb ischemiamales
Associations
5Homocitrulline
upin humans1
1 study
Homocitrulline
upin humans1
Homocitrulline is associated with critical limb ischemia in humans after adjustment for traditional risk factors.
Humansafter adjustment for traditional risk factors27 yearsn = 3,759
Circulating metabolites
upin humans1
1 study
Circulating metabolites
upin humans1
Circulating metabolites predict critical limb ischemia in humans (prospective cohort with median follow-up of 27 years) (∆C statistic, 0.041 [95% CI, 0.018-0.064]).
Humansprospective cohort with median follow-up of 27 years27 yearsn = 3,759
Tirzepatide
downin humans1RR 0.5
1 study
Tirzepatide
downin humans1RR 0.5
Tirzepatide is linked with a lower risk of critical limb ischemia in humans (compared with injectable semaglutide, propensity-matched cohort) (RR 0.50 (95% CI 0.39-0.63)).
Humanscompared with injectable semaglutide, propensity-matched cohortn = 24,274
Dementia prevalence
upin humans1+8% prevalence
1 study
Dementia prevalence
upin humans1+8% prevalence
Critical limb ischemia is associated with dementia prevalence in humans (critical limb ischemia) (8% prevalence).
Humanscritical limb ischemian = 369
Mortality
upin humans1
1 study
Mortality
upin humans1
Critical limb ischemia is associated with mortality in humans (Relative to the Dutch population, adjusted for age and gender) (Mortality rate ratio 3.13 (95% CI 2.00–4.66); 24 deaths).
HumansRelative to the Dutch population, adjusted for age and genderboth; 27 womensn = 36
Trial sponsors
Company1 trialPhase 3250 people
Company1 trialPhase 330 people
Company1 trialPhase 224 people
Company1 trialPhase 1/220 people
1 trialPhase 4390 people
University of California, San Francisco
1 trialPhase 433 people
1 trialPhase 418 people
Science Valley Research Institute
1 trialPhase 3200 people
Funding
2 grants since 2016Japan Society for the Promotion of Science¥3.9MNational Heart, Lung, and Blood Institute$533K